Monoclonal antibodies

ProMIS Neurosciences Issues Chairman’s Memorandum

Retrieved on: 
Mercredi, août 4, 2021

TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.
  • We are in a new era in the fight against Alzheimers, ALS, and other neurodegenerative diseases, stated Eugene Williams, Executive Chairman of ProMIS Neurosciences.
  • The Chairmans memorandum highlights the recent FDA accelerated approval of Biogens Aduhelm (aducanumab) which now provides a regulatory path to approval in AD, opening the door to development of next generation therapies selectively targeting the pathogenic forms of amyloid-beta.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

Retrieved on: 
Mercredi, août 4, 2021

The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.

Key Points: 
  • The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.
  • The partnership, which spans several therapeutic areas, will help to rapidly expand EQRxs early-stage pipeline of novel medicines.
  • Were proud to partner with EQRx on their bold mission to reimagine drug development and bring medicines to patients faster and at lower cost, said Carl Hansen, Ph.D., CEO of AbCellera.
  • EQRx is committed to catalyzing a market-based solution to one of societys biggest healthcare challenges by developing important new medicines and offering them at lower prices.

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

Retrieved on: 
Mercredi, août 4, 2021

The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.

Key Points: 
  • The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.
  • The partnership, which spans several therapeutic areas, will help to rapidly expand EQRxs early-stage pipeline of novel medicines.
  • Were proud to partner with EQRx on their bold mission to reimagine drug development and bring medicines to patients faster and at lower cost, said Carl Hansen, Ph.D., CEO of AbCellera.
  • EQRx is committed to catalyzing a market-based solution to one of societys biggest healthcare challenges by developing important new medicines and offering them at lower prices.

U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration

Retrieved on: 
Mardi, août 3, 2021

Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.

Key Points: 
  • Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.
  • Entitled Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial , this paper describes the treatment effect of risuteganib 1.0 mg in patients with intermediate dry AMD.
  • These clinical data suggest that risuteganib can reverse vision loss and restore functional vision in patients with intermediate dry AMD with treatment at a 12-week interval.
  • Phase 2a study with risuteganib in less advanced dry AMD met its primary endpoint of vision recovery.

Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation

Retrieved on: 
Mardi, août 3, 2021

TARRYTOWN, N.Y., Aug. 3, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced winners of the ninth annual Regeneron Prize for Creative Innovation, a competition designed to recognize creativity and independent scientific thinking among postdoctoral fellows and graduate students focused on biomedical research.

Key Points: 
  • TARRYTOWN, N.Y., Aug. 3, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced winners of the ninth annual Regeneron Prize for Creative Innovation, a competition designed to recognize creativity and independent scientific thinking among postdoctoral fellows and graduate students focused on biomedical research.
  • Each winner received $50,000 in prize money, along with a $5,000 donation to their institution, and ten additional finalists were awarded $5,000 each.
  • "This year's winners and finalists once again demonstrated the power and innovative spirit of the next generation of scientists.
  • For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

Retrieved on: 
Lundi, août 2, 2021

The NOVA study provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the real-world findings1,2,3, said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen.

Key Points: 
  • The NOVA study provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the real-world findings1,2,3, said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen.
  • A complete analysis of the study data is ongoing and detailed results will be shared in a future scientific forum.
  • Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
  • No Difference in Radiologic Outcomes for Natalizumab Patients on Extended Interval Dosing Compared with Standard Interval Dosing in MS PATHS.

Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021

Retrieved on: 
Lundi, août 2, 2021

Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated We are especially pleased Professor Nanchahal can present his scientific work to clinical colleagues who have extensive experience of treating patients with late-stage disease.

Key Points: 
  • Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated We are especially pleased Professor Nanchahal can present his scientific work to clinical colleagues who have extensive experience of treating patients with late-stage disease.
  • Professor Jagdeep Nanchahal commented, By systematically analyzing tissues normally discarded at the time of surgery, we were able to identify a potential therapeutic target and progress through to testing in patients with early stage Dupuytrens disease.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.
  • The Companys primary, most advanced platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor) which is in the clinic.

Regeneron Pharmaceuticals (REGN) Long-Term Investor Alert: Contact Johnson Fistel Regarding Investigation

Retrieved on: 
Vendredi, juillet 30, 2021

SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) against certain of its current and former officers and directors.

Key Points: 
  • SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) against certain of its current and former officers and directors.
  • Regeneron allegedly paid these substantial sums only after confirming that the foundation needed the money to cover co-pays only for Eylea and not for competing drugs.
  • If you are a current, long-term shareholder of Regeneron, holding shares since 2013, and are interested in learning more about the investigation, please contact Jim Baker ( [email protected] )by email or phone 619-814-4471.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.

FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)

Retrieved on: 
Vendredi, juillet 30, 2021

REGEN-COV is not a substitute for vaccination against COVID-19, and is not authorized for pre-exposure prophylaxis to prevent COVID-19.

Key Points: 
  • REGEN-COV is not a substitute for vaccination against COVID-19, and is not authorized for pre-exposure prophylaxis to prevent COVID-19.
  • This authorization enables these groups to use REGEN-COV to prevent infection in post-exposure and certain institutional settings.
  • REGEN-COV has not been approved by the FDA, but is currently authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under section 564(b)(1) of the Act, 21 U.S.C.
  • Consequently, REGEN-COV remains available for use across the U.S., and Regeneron will continue actively monitoring the potency of REGEN-COV against emerging variants.

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021

Retrieved on: 
Vendredi, juillet 30, 2021

ICARE AD-US, a prospective study of ADUHELMTM (aducanumab-avwa) 100 mg/mL solution for injection, is designed to collect real-world, long-term effectiveness and safety data on ADUHELM.

Key Points: 
  • ICARE AD-US, a prospective study of ADUHELMTM (aducanumab-avwa) 100 mg/mL solution for injection, is designed to collect real-world, long-term effectiveness and safety data on ADUHELM.
  • The virtual oral session (#57522) was titled, "ICARE AD-US: design of a prospective, single-arm, multicenter, noninterventional real-world study of aducanumab in United States."
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • The presentation on the ICARE AD-US study will be available for 30 days on the AAIC conference website.